Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

October 30, 2024 4:16 PM EDT

Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

October 30, 2024 4:03 PM EDT

BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More